Tarsus Pharmaceuticals, Inc. Presents New Saturn-1 Pivotal Trial Data and Titan Real-World Prevalence Study Results at ASCRS 2021 - Press Release
New Saturn-1 data demonstrated a strong patient responder rate with 95% of Demodex blepharitis patients treated with TP-03 achieving ≤0.5 mites per lash and 93% improving by at least one collarette grade Further Saturn-1 safety analysis revealed that TP-03 had a favorable safety profile with no clinically significant effect on multiple measures Titan study reveals the high real-world prevalence of Demodex blepharitis, with collarettes present in 58% of U.S. patients visiting an eye doctor IRVINE, Calif., July 24, 2021 (GLOBE NEWSWIRE) — Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), a late ...
Source: wiredprnews.com